CNTG News and Press, Centogene N.V.

TUCSON, Ariz. and CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 20, 2024 (GLOBE NEWSWIRE) -- Critical Path Institute (C-Path), a leader in forming collaborations that accelerate drug development, and Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answer...

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 31, 2024 (GLOBE NEWSWIRE) -- CENTOGENE N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the voting results of the Company ...

CXApp Inc. (CXAI) is expected to report for quarter end 2024-03-31 Purple Biotech Ltd. (PPBT) is expected to report $-0.15 for Q1 2024 AutoZone Inc. (AZO) is expected to report $35.72 for Q3 2024 Turkcell Iletisim Hizmetleri AS (TKC) is expected to report for Q1 2024 Orkla ASA ADR...

Centogene N.V. (CNTG) is expected to report for Q4 2023

Reported Full Year 2023 total revenues of 2% growth at €48.5 million Secured approximately USD 20 million – strengthening cash position and expanding relationship with Lifera, a biopharma company owned by the PIF Positioned for strong performance in 2024, driven by new ...

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, May 15, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced it has entered into a set of agreements with Lifera, a biopharmaceu...

CENTOGENE to receive license fee providing Evotec with R&D license to complete next phase of pre-clinical research Companies amend existing drug discovery partnership for Evotec to lead continued development. Upon Evotec exercising its option, CENTOGENE to receive an option exercise f...

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, May 10, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today revealed significant growth in the CENTOGENE Biodatabank, the worldȁ...

2024-04-02 16:36:49 ET More on Centogene Centogene, Takeda extend diagnostic partnership Centogene to explores strategic alternatives, gets Nasdaq delisting notice; shares plunge Seeking Alpha’s Quant Rating on Centogene Historical earnings data for Ce...

2024-03-19 07:41:32 ET More on Centogene, Takeda, etc. Takeda Pharmaceutical: Eohilia's FDA Approval Brings Tailwinds Takeda Pharmaceutical Company: Attractive Stock But Needs To Grow Net Profits Takeda Pharmaceutical Company Limited 2023 Q3 - Results - Earnings Call...